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INTRODUCTION 
          
 
 
 
 
 
 
 
 
 
Pregnancy with jaundice is considered as high risk pregnancy. Jaundice 
affects a small percentage of pregnant women, yet it takes a major toll on health of 
both mother and fetus especially in developing countries like India. 
It complicates 3-5% of pregnancies and is one of the important causes of 
maternal and neonatal morbidity and mortality worldwide. Throughout the 
pregnancy there exists alteration in normal physiological and hormonal profiles.  
Incidence of jaundice in pregnancy is 0.4-0.9/1000 in India.  
  It could be peculiar to the pregnancy such as acute fatty liver of pregnancy, 
recurrent cholestatic  jaundice in pregnancy and jaundice complicating 
preeclampsia of pregnancy.  
It can be concurrent with pregnancy such as due to infective pathology like 
viral hepatitis and also due to preeclampsia ,HELLP,Acute fatty liver in 
pregnancy,intrahepatic cholestasis in pregnancy, hyperemesis gravidorum,Wilson 
disease,cirrhosis with portal hypertension  or it could be due to drugs administered 
during pregnancy 
The present study analyses the cause of the disease, altered liver function, 
maternal and fetal morbidity and mortality and preventive measures in jaundice 
complicating pregnancy. This study will be helpful in better understanding and 
improving the maternal and perinatal outcome in jaundice complicating pregnancy 
 
 
 
 
  
 
 
AIM OF THE STUDY 
 
 
 1. Studying the incidence of non infective jaundice in pregnant women in this 
tertiary care centre 
2. To enumerate the various causes of non infective jaundice in pregnancy 
3. To follow the course of the disease and the numerous complications it 
ensues 
4. To form a preplanned algorithm of investigations to diagnose non infective 
jaundice in pregnancy 
5. To study the best protocol for the management of non infective jaundice in 
pregnancy 
6. To follow maternal and fetal outcomes in non infective jaundice in 
pregnancy 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
REVIEW OF LITERATURE 
 
 
 
 
During the state of pregnancy, the human body undergoes a multitude of 
changes in the process of its acclimatisation to the growing fetus. Inspite of most of 
these changes being physiological, the potential for morbidity and mortality to both 
mother and fetus is a real threat.  
Liver is prominent as the bed of many important metabolic and synthetic 
functions of the body. In pregnancy, the liver is not palpable normally. Serum 
albumin concentrations decreases due to rise in plasma volume. ALP rises in third 
trimester as a result of rise in placental ALP and bone iso-enzyme. Serum 
transaminases increase only during labour as a consequence of leakage from 
uterine muscles. 3%-5% of pregnancies show abnormal liver function tests. The 
potential causes are coexisting liver disease (commonest being viral hepatitis or 
gallstones) and underlying chronic liver disease. A kaleidoscopic range of liver 
diseases are encountered in pregnancy.  
The liver could be targeted by diseases specific to the pregnancy like the 
intrahepatic cholestasis of pregnancy and the acute fatty liver of pregnancy, there 
being a paucity of available means which may be used to predict how and when 
such illnesses may occur with reasonable certainity. India, being a tropical country, 
shows a high morbidity and mortality statistics due to liver diseases in pregnancy. 
Also, morbidity is more likely to occur in the presence of a preexisting liver 
disease in a pregnant woman as in autoimmune hepatitis or when a new onset liver 
disease occurs during the period of gestation as in herpes simplex hepatitis.  
Many physiologic changes which are the norm during pregnancy could pose 
problems in evaluating hepatobiliary function because they may misleadingly 
appear as pathological. For instance, the plasma volume expands during pregnancy 
following retention of salt and water. This leads to a state of hemodilution. .  
These changes which peak during the second trimester later plateau until 
delivery. As a result, serum levels of uric acid, total protein, albumin, and 
hematocrit are lowered. On the other hand, serum alkaline phosphatase levels may 
rise in third trimester as a result of placental production, while serum values of 
liver enzymes namely aspartate aminotransferase (AST), alanine aminotransferase 
(ALT), gamma-glutamyl transpeptidase (GGT), and also the bilirubin and 
prothrombin time remain well within the normal range.  
Oestrogens favour biliary cholesterol saturation and also inhibit the hepatic 
synthesis of chenodeoxycholic acid, while progesterone plays a role in decreasing 
the gall bladder contractility and favours lithogenicity leading to the accumulation 
of sludge and gallstone formation. But when appropriately and timely diagnosed 
and managed, the outcome may be positive and the liver disease in pregnancy 
could resolve on its own without any chronic consequences in the future.   
Although there exists various associations between hepatic dysfunction and 
pregnancy, it is to be re emphasized that hepatic disease is a rarity in pregnancy. 
The leading cause of jaundice in pregnancy is acute viral hepatitis. The course of 
acute hepatitis is not affected in pregnancy in all viral hepatitis except hepatitis E 
virus which is associated with many complications which peak in the third 
trimester of gestation.  
The liver is the hot house of a myriad functions- the biotransformation of 
those compounds which are insoluble (i.e bilirubin, drugs, toxins), the metabolism 
and excretion of cholesterol and bilirubin, the synthesis of plasma proteins (i.e 
albumin, globulin, coagulation factors, transferrin, haptoglobin), and amino acid 
metabolism, carbohydrates and lipid metabolism. Pregnant women with chronic 
liver disease show a higher risk of fetal loss during gestation. Pre-eclampsia 
especially when associated with HELLP syndrome results in an increase in  
maternal and fetal morbidity and mortality.  
There is no single liver function test which successfully quantifies liver 
disease. A rise in level of AST and ALT predict liver cell necrosis, while synthetic 
function is quantified by ranging albumin level and determining prothrombin time. 
Cholestasis and biliary obstruction are determined by measuring the levels of 
bilirubin, alkaline phosphatase, gamma glutamyl transpeptidase and 5-
nucleotidase. In normal pregnancies, there may be an increase in ALP which is a 
result of placental ALP 
Though liver is not palpable in normal pregnancy, palmar erythema and 
vascular nevi may appear in pregnancy. Serum biochemical tests show increase in 
alkaline phosphatase and cholesterol and serum bile acid in the last trimester . This 
elevation rarely exceeds two or four folds the non pregnant value and mainly is of 
placental origin. Also serum albumin concentration may fall to values 0-60% than 
those in the non gravid state secondary to the increase in plasma volume. Changes 
in liver function is also confirmed by reduced bromsulphthalein uptake.  
The point to be noted is that blood flow constitutes 35% of the cardiac 
output in nongravid patient, in contrast during pregnancy it falls to 28% as the 
remaining blood is shunted through the placenta. Therefore liver is one of the 
primary organs affected during pregnancy due to metabolic and hormonal changes 
associated with gestation. 
Jaundice in pregnancy is considered as high risk pregnancy. Though 
Jaundice affects just a small percentage of pregnant women, yet it plays a major 
detrimental role on health of both the mother and fetus especially in our country. 
 
It complicates 3-5% of all pregnancies and is one of the leading causes of 
maternal , fetal and neonatal morbidity and mortality all over the world . 
Throughout the pregnancy there appears changes in both normal physiological and 
hormonal profiles. 
Incidence of jaundice in pregnancy in India is 0.4-0.9/1000.  It could be 
specific to the gestation such as acute fatty liver of pregnancy or recurrent 
cholestatic jaundice of pregnancy or jaundice complicating toxemia of pregnancy. 
It may occur concurrently with pregnancy such jaundice caused by infective 
pathology like viral hepatitis or jaundice due to gallstones or it may be a result of 
drugs administered during the gestational period. 
My current study analyses the cause of the disease, altered liver function 
,maternal and fetal morbidity and mortality and preventive measures in jaundice 
complicating pregnancy as well as the outcome of the disease and the course of the 
pregnany. This study will play a role in understanding better and improving the 
maternal and perinatal outcome in jaundice complicating pregnancy. 
 
While taking into consideration  liver disease complicating pregnancy, it is 
useful to use Sherlock's classification  and group 
1) liver disease specific to pregnancy; 
2) intercurrent liver disease co existing in pregnancy; 
3) pregnancy complicating liver disease 
-Jaundice specific to pregnancy such as cholestasis of pregnancy or pre eclampsia 
 -Jaundice aggravated by pregnancy which include viral hepatitis like Hepatitis B, 
Hepatitis E, Herpes Simplex virus infection during pregnancy leading to fulminant 
hepatic failure  
-Jaundice due to liver disorders which are pre existing like Wilson’s diseases and 
chronic active hepatitis. 
Viral hepatitis leads as the commonest cause of jaundice associated with 
pregnancy. The incidence of hepatitis varies markedly in different parts of the 
world. The incidence is around 0.1% in developed countries but it can range from 
3-20% or more in developing countries. In developed countries there is not much 
of a difference in the course of the jaundice in both pregnant and non pregnant 
women in however the incidence of maternal morbidity and mortality presented 
with fulminant hepatitis is higher in developing countries. 
 Liver Disease in Pregnancy Jaundice in Pregnancy May Be 
A) Intercurrent In Pregnancy 
B) Specific To Pregnancy 
C) Acute On Underlying Chronic Disease 
 
A) Intercurrent In Pregnancy  
1. Viral hepatitis 
2.  Drug induced 
3. Gall stones 
 
B) Specific To Pregnancy 
1. Cholestatic jaundice 
2. Acute fatty liver of pregnancy 
3. HELLP syndrome 
 
C) Underlying Chronic Liver Disease 
1. Cirrhosis of liver 
2. Chronic hepatitis 
 
 Physiological Changes during Pregnancy 
 Increase  
1. Plasma volume, cardiac rate and rise in cardiac output by    
35%-50% which peaks at 32 weeks. Furthermore it increases by 20% occur 
in twin pregnancies  
2. Alkaline phosphatase levels increase to around 150U/L from pre pregnant 
values of 30- 115U/L 
3. Rise in clotting factors 
4. Rise in Ceruloplasmin 
5. Increase in Transferrin 
6. Increase CRP, C3 and C4 
 Decrease 
1. Gallbladder contractility decreases. 
2. Uric Acid level decreases 
3. Fall in total protein ( pre pregnancy 6.7- 8.6g/dl to 5-7 g/dl in third trimester) 
and Albumin pre pregnancy 4.1- 5.3g/dl to 2.3 -4g/dl in third trimester) 
4. Decrease in Antithrombin III and protein S 
5. Modest or no fall in platelet levels  
No Change 
1. Liver transaminase levels (AST, ALT) remain unaltered 
2. GGT remains the same 
3. Bilirubin level  is unaltered by pregnancy 
4. Prothrombin time remains the same 
5. Blood flow to the liver follows the same pre pregnant pattern. 
HYPEREMESIS GRAVIDARUM (0.3- 2%) 
Hyperemesis gravidarum is intractable nausea and vomiting during 
pregnancy which results in fluid and electrolyte imbalance, 5% weight loss or 
greater, and nutritional deficiency which requires hospital admission. The 
incidence of hyperemesis gravidarum ranges from 0.3%-2% of all live births It 
occurs  usually between the 4th and 10th week of gestation and resolves by the 20th 
week.  
           Risk factors for Hyperemesis include multiple pregnancies , molar 
pregnancy, trophoblastic disease, hyperemesis in previous pregnancy and fetal 
abnormalities (triploidy, trisomies and hydrops fetalis). Liver function test 
abnormalities are also common in hyperemesis and resolve when the vomiting is 
controlled. 
 Liver is involved in around 50%-60% of patients with Hyperemesis . Most 
commonly mild serum aminotransferases elevations are seen, but cases of severe 
transaminase elevations (alanine aminotransferase (ALT) levels 400 to over 1000 
U/L) have been reported. Mild hyperbilirubinemia presenting as mild jaundice can 
be seen as well. Other complications are disturbances in electrolytes and in water 
and acid-base balance which usually resolve when treated adequately with 
hydration. 
Available data suggest minimal or no differences between fetuses born to 
mothers with Hyperemetic and non-Hyperemetic mothers . A large cohort study 
showed that infants of hyperemetic mothers were found to be of lower birth 
weights and showed higher rates of being small for gestational age . Treatment of 
Hyperemesis is mainly supportive.  Patients must avoid triggers that aggravate 
their nausea, and eat small, frequent, meals low in fat. Intravenous fluids, folate 
and thiamine supplementation and antiemetic therapy may be given. The first line 
agent is Promethazine, but other medications such as ondansetron, and steroids 
have been tried. 
 
PREECLAMPSIA /ECLAMPSIA 
 
Preeclampsia is diagnosed by the triad of hypertension, edema, and 
proteinuria. It is encountered in about 5%-10% of all pregnancies and occurs well 
into the second trimester or in the third trimester of pregnancy. In pregnancy, 
hypertension is defined as a systolic pressure more than 140 mmHg and a diastolic 
pressure more than 90 mmHg on at least two occasions which are atleast 4 to 6 
hours apart in a patient who was previously normotensive.  
Proteinuria is quantified as equal to or more than 300 mg of protein in a 24 h 
urine collection which corresponds to 1+ protein or more on urine dipstick test of 
two random urine samples collected 4 to 6 h apart. Eclampsia includes all the 
features of preeclampsia along with neurologic symptoms including  headache, 
visual disturbance and seizures or coma. The risk factors for preeclampsia and 
eclampsia are nulliparity, extremes of maternal age, insulin resistance, obesity, and 
infection. The pathology of preeclampsia and eclampsia is involves  procoagulant 
and proinflammatory states that lead to rise in vascular permeability and a systemic 
inflammatory response that contributes to end organ damage due to hypoperfusion.  
Organ dysfunction in severe preeclampsia includes  hepatomegaly and 
hepatocellular injury.  7.5% of all pregnancies are affected, but only 25% of 
preeclampsia cases turn severe. Liver involvement is not an usual feature and when 
it occurs symptoms are non-specific. 
 Eclampsia occurs when grand mal seizures occur. Liver involvement can 
present with epigastric or right hypochondrial  pain, from hepatomegaly  causing a 
stretch of Glisson’s capsule. Liver injury is a consequence of vasoconstriction and 
fibrin precipitation in the liver cells. Complications can include hematoma under 
Glisson’s capsule and hepatic rupture . 
The depth of the liver biochemistry abnormalities parallels the maternal risks 
but not fetal outcomes. Liver function tests cannot exclusively be used to make 
clinical decisions, as the normal liver function tests does not rule out the disease. 
An expectant approach can be used  till after 34 weeks gestation to limit fetal 
morbidity.  
 
Laboratory values are altered which include 10- to 20 times elevation in 
aminotransferases, alkaline phosphatase levels that exceed the normal values 
observed in pregnancy and bilirubin rises but less than 5 mg/dL. The histology of 
the liver generally shows periportal hemorrhage, hepatic sinusoidal deposition of 
fibrin, hepatocyte necrosis, and in severe conditions liver infarction. It is thought 
that these changes are mostly because of vasoconstriction of hepatic vasculature.           
 
  Microvesicular fatty infiltration has been reported in some cases of 
preeclampsia,  showing a possible overlap with the mechanism of acute fatty liver 
of pregnancy. Maternal mortality from preeclampsia and eclampsia is much 
reduced in developed countries but in developing countries it may reach 15%- 
20%. The fetal mortality rate is low, occurring only in 1%-2% of births. The only 
effective treatment for preeclampsia is delivering the fetus and placenta. 
Pharmacological agents administered in preeclampsia are antihypertensives such as 
labetalol. Magnesium sulphate may be administered if eclampsia develops.  
 
HEMOLYSIS, ELEVATED LIVER TESTS AND LOW PLATELETS 
(HELLP) (0.5 – 0.9%) 
 
HELLP syndrome is a multi systemic disorder exclusive to pregnancy 
presenting with hemolysis, elevated liver enzymes, and low platelets. Almost 70% 
of cases occur antenatally, more during the third trimester of pregnancy. 
  The pathophysiology of HELLP is alterations in platelet activation, leading 
to an increase in proinflammatory cytokines, and segmental vasospasm along with 
vascular endothelial damage. A distant association with a defect in long-chain 3-
hydroxyacylcoenzyme A dehydrogenase (LCHAD) enzyme has been suspected, 
suggesting a possible overlap of HELLP syndrome and acute fatty liver of 
pregnancy. 
Patients usually present with right hypochondrial abdominal pain, vomiting, 
malaise, and pedal edema. Other associated conditions include antiphospholipid 
syndrome and diabetes insipidus. 
Other late features of HELLP include disseminated intravascular 
coagulopathy (DIC), placental abruption, pulmonary edema and retinal 
detachment. Laboratory findings feature hemolysis along with increased bilirubin 
levels (usually less than 5 mg/dL) and lactate dehydrogenase (LDH) levels greater 
than 600 IU/L, moderate elevation of aspartate aminotransferase (AST) and ALT 
levels (200 IU/L to 700 IU/L), and thrombocytopenia (less than 100000/mL). In 
early presentations, prothrombin time and activated partial thromboplastin time are 
within normal range, but in later phases, DIC may occur with increasing levels of 
fibrin degradation products, D-dimer and thrombin- antithrombin complex. 
Although HELLP typically presents in late second trimester or third 
trimester between 28 and 36 weeks of gestation, 30% show symptoms in the first 
seven days postpartum. The hypertension-related liver diseases often show similar 
presentations so differentiation is difficult, as usually there is overlap in their 
features. The diagnosis of HELLP is mostly made by typical laboratory results. 
Signs of hemolytic anemia and thrombocytopenia with platelets less than 10000/l 
or abdominal pain radiating to the right shoulder, cross-sectional imaging can 
exclude hepatic complications more accurately than ultrasound. 
 Hepatic infarction can be suspected with right upper quadrant pain and 
fever whereas abdominal distension and shock can occur with hepatic rupture. 
Surgery is the dictum only for those with enlarging hematomas or showing 
evidence of rupture along with features of hemodynamic instability.On the other 
hand, successful percutaneous embolization of the hepatic arteries in stable women 
has been reported.  
Pathophysiology includes intravascular fibrin deposition and sinusoidal 
obstruction that can result in hepatic infarction. Histologically focal hepatocyte 
,peri portalnecrosis is seen, Hemorrhage and fibrin deposits. The maternal 
mortality from HELLP is reported to 1%. The perinatal mortality rate is around 
7%-22% and may be due to premature detachment of placenta, intrauterine 
asphyxia of the fetus and prematurity.  
Other complications of HELLP syndrome are acute renal failure, pulmonary 
edema, stroke, adult respiratory distress syndrome liver failure, and hepatic 
infarction. The only curative treatment for HELLP syndrome is delivery.  
        If the pregnant woman is more than 34 week gestation, immediate termination 
is the treatment. If the gestational age falls between 24 week and 34 week, 
corticosteroids are given to accelerate fetal lung maturity in order to prepare for 
delivery 48 hours later. After delivery, the mother should be closely monitered, as 
data shows worsening thrombocytopenia and increasing LDH up to 48 hours 
postpartum. But laboratory values (transaminases, bilirubin and LDH) normalize in 
48 hours. For patients with worsening postpartum symptoms of HELLP, 
antithrombotic agents, plasmapheresis and dialysis may be tried.  
 
ACUTE FATTY LIVER OF PREGNANCY (1 in 10,000 to 1 in 20,000) 
Acute fatty liver of pregnancy (AFLP) is a rare and severe maternal illness 
that occurs in late pregnancy. The incidence is 1 in 10 000 to 1 in 15 000 
pregnancies, but it has a maternal mortality rate of 18% and shows a fetal mortality 
rate of 23%. AFLP is more in nulliparous women and those 
with multiple gestation.  
The pathogenesis of AFLP is the defect  in mitochondrial fatty acid beta-
oxidation. In normal circumstances, an women who is heterozygous for enzymatic 
mutations in fatty acid oxidation enzyme will not show abnormal fatty oxidation. 
But when the same heterozygous woman carries a fetus which is homozygous for 
such mutations, fetal fatty acids begin to accumulate and is transferred to the 
mother’s circulation. This extra load of long chain fatty acids and triglyceride 
accumulation becomes too much for the mother’s enzymes to handle and result in 
hepatic fat deposition and therefore impaired hepatic function in the mother. 
  A deficiency in long chain 3-hydroxyacyl-CoA dehydrogenase (LCHAD) is 
associated with the development of AFLP. LCHAD is a constituent of the enzyme 
complex , the mitochondrial trifunctional protein (MTP), and it is known that the 
G1528C and E474Q mutations of the MTP play a role in causing LCHAD 
deficiency that leads to AFLP. Patients with AFLP usually present with a 2 week 
history of nausea, vomiting, abdominal pain. Jaundice is a common occurrence, 
and some women have moderate to severe hypoglycemia, hepatic encephalopathy, 
and coagulopathy. 
Around 50% of these patients will show signs of preeclampsia, although 
hypertension is usually not in the severe range.   Laboratory findings include rise in 
aminotransferase levels, from being mildly elevated to approaching 1000IU/L. 
        Since AFLP causes significant maternal and fetal morbidity and mortality, 
early diagnosis must be made. The gold standard test is liver biopsy. 
Histopathology reveals pale, swollen hepatocytes in the central zones surrounded 
with microvesicular fatty infiltration which can be identified on frozen section with 
oil red O staining. Electron microscopy reveals mega-mitochondria and para 
crystalline mitochondrial inclusions.  
        Although liver biopsy is the standard investigation to confirm the diagnosis, it 
is usually not done because of coexisting coagulopathy. Hence the diagnosis of 
AFLP is usually made on basis of clinical and laboratory findings. 
        As with most pregnancy-related liver diseases, the definitive treatment of 
AFLP is delivering of the fetus. Rarely, patients will end up in fulminant hepatic 
failure necessitating liver transplantation . Careful monitoring of the infant is 
warranted as there is increased risk of cardiomyopathy, neuropathy,  
hypoglycemia, hepatic failure, and death associated with fatty acid oxidation 
defects in newbown 
        The median gestation at the time of identification is 36 weeks. Risk factors 
are twin pregnancies and low body mass index. Therefore early recognition,  
immediate  delivery  and care are essential to improve maternal and fetal 
prognosis, as the postpartum course is dependent on the interval between 
development of symptoms and termination of the gestation. If hepatic function is 
not rapidly corrected, liver transplantation offers the patient the best chance for 
survival. Concomitant preeclampsia is seen in one half of the affected women. 
Aminotransferase elevations and hyperbilirubinemia are typically seen. Hepatic 
failure can show signs of hepatic dysfunction such as encephalopathy, 
coagulopathy, and hypoglycemia. Renal dysfunction and pancreatitis are also 
common. The Swansea Criteria is a combination symptoms and laboratory 
derangements . These criteria has been supported in a large cohort in England, 
where the incidence of AFLP is 5 cases per 100,000 maternities. The Swansea 
Criteria has agreement with the clinical diagnosis of AFLP. Although there was 
only 1 death in this study group 65% were admitted to an intensive care unit . 
When the Swansea Criteria were applied in a large group of women with  
pregnancy related liver disease liver biopsy was taken, this offered an 85% positive 
predictive value and a total 100% negative predictive value for hepatic 
microvesicular fatty infiltration.  
                   
INTRAHEPATIC CHOLESTASIS OF PREGNANCY (1.5- 2%) 
 
Intrahepatic cholestasis of pregnancy (ICP), also known as obstetric 
cholestasis, is a rare pregnancy specific liver condition that occurs in the late 
second or third trimester and has a prevalence of about 1/1000 to 1/10 000. IHCP 
is the most common liver disease in pregnancy with prevalence ranging between 
0.3 and 5.6%. It is significantly more common in South Asia, South America  and 
Scandinavian countries. 
 ICP is more common in women of advanced maternal age, multiparous 
women, and in women with a personal history of cholestasis with oral 
contraceptive use . ICP has good prognosis, but it is associated with increased fetal 
morbidity and mortality, particularly from chronic placental insufficiency, preterm 
labor, fetal distress, and intrauterine death. 
The cause of ICP is likely multifactorial. Mutations in the phospholipid 
translocator known as the ATPcassette transporter B4 (ABCB4) or multidrug 
resistant protein-3 (MDR3) are associated with the development of ICP. Changes 
caused by these genetic mutations lead to increased sensitivity to estrogen, which 
impairs the sulfation and transportation of bile acids. Estrogens are thought to act 
on hepatocytes by decreasing membrane permeability and bile acid uptake by the 
liver. The maternal-to fetal transfer of bile acids across the placenta becomes 
impaired, leading to potentially toxic bile acid levels in the fetus. The elevation in 
bile acid levels is also thought possibly to affect myometrial contractility and to 
cause vasoconstriction of chorionic veins in the placenta, which may contribute to 
preterm deliveries and fetal distress seen in ICP 
Pruritis is the the classic symptom that usually begins in the second or third 
trimester. It usually occurs in the palms and soles and may progress to the rest of 
the body, and worse at night.  Pruritus may be severe in some cases.  
        Jaundice occurs in approximately 10%-25% of patients and may appear 
within the first four weeks of the onset of pruritus . ICP women has more 
Cholelithiasis and cholecystitis . Abnormal laboratory findings include elevated 
total bile acid levels up to 10- to 25-fold, with an increase in cholic acid and a 
decrease in chenodeoxycholic acid leading to a marked elevation in the cholic/ 
chenodeoxycholic acid ratio.  
        Bilirubin levels may be elevated, but are usually less than 6 mg/dL. Serum 
alkaline phosphatase levels may also be elevated, but this is usually less helpful to 
follow given typical alkaline phosphatase elevations seen in pregnancy. Liver 
biopsy is usually not required to make the diagnosis of ICP. 
The treatment of choice for ICP is ursodeoxycholic acid (UDCA), which 
helps to relieve pruritus and improve liver function test abnormalities. Other 
medications, such as cholestyramine and S-adenosyl-L-methionine, have been 
associated with improving pruritus and normalizing biochemical profiles, but 
studies have found UCDA to be superior over cholestyramine and S-adenosyl- L-
methionine . Dexamethasone has also been used, but has shown to be much less 
effective in reducing bile acids and bilirubin and ineffective in relieving pruritus . 
Antihistamines are frequently used to alleviate pruritus, and vitamin K and other 
fat-soluble vitamin supplementation should also be administered if fat 
malabsorption is suspected. 
 
CHRONIC LIVER DISEASE AND PORTAL 
HYPERTENSION 
Women with significant hepatic dysfunction has decreased fertility due to 
hypothalamic-pituitary dysfunction. However, cirrhosis is not a contraindication, 
as pregnancy may be tolerated if cirrhosis is well-compensated and without 
features of portal hypertension . Portal hypertension leads to increased maternal 
complications, including variceal hemorrhage , hepatic failure, encephalopathy, 
jaundice, malnutrition , and splenic artery 
aneurysm . 
Bleeding from esophageal varices has been reported in 20%-25% of 
pregnant women with cirrhosis . All pregnant women with cirrhosis should be 
screened for varices starting in the second trimester and started on beta-blockers if 
indicated. 
The treatment of variceal bleeding consists of both endoscopic and 
pharmacologic treatment but in this time and age the management for varices is 
prophylactic with beta blockers or endoscopic variceal ligation. However, 
vasopressin is avoided as it has been shown to cause placental ischemia, necrosis, 
and amputation of fetal digits and is contraindicated in pregnancy. 
        There are no published systematic reviews on the management of cirrhosis or 
portal hypertension during pregnancy, likely because of the low prevalence of 
cirrhosis in women of reproductive age and reduced fertility of women with 
cirrhosis. Pregnant women with cirrhosis should ideally be managed in a 
multidisciplinary setting with maternal–fetal medicine along with 
gastroenterology. Pregnancy in women with underlying cirrhosis has been 
associated with an increase in prematurity, spontaneous abortions, and maternal–
fetal mortality. 
            Non-cirrhotic portal hypertension has better outcomes than cirrhotics with 
portal hypertension . Variceal bleeding is the most common  complication of portal 
hypertension during pregnancy, with an increased risk at delivery and the second 
trimester, aggravated by an increase in intravascular volume, compression from the 
gravid uterus. Up to 30% of cirrhotic pregnant women bleed from esophageal 
varices during pregnancy, and the risk of variceal bleeding increases up to 50–78% 
if there are pre-existing varices . Each episode of variceal bleeding leads to 
maternal mortality rates as high as 20–50%, with an even higher risk of fetal loss . 
Variceal bleeding during pregnancy is managed very similarly to variceal 
bleeding in general given the acute and life-threatening nature of the event, with a 
focus on endoscopic hemostasis and supportive care for the mother and fetus.  
Octreotide is a pregnancy category B drug and appears to be safe as an adjunct 
treatment in acute variceal bleeding along with antibiotics.  
 Endoscopy during pregnancy appears safe, but must be considered carefully 
in terms of the indication for endoscopy, the risks vs benefit evaluation and 
whether it will lead to management changes . Given the risks of variceal bleeding 
in cirrhotic women during pregnancy, the significantly increased mortality 
associated with such bleeding, and the opportunity to intervene if varices are 
identified preemptively, the indications for screening for esophageal varices 
appears to have at least a moderate indication. Considered against the small, but 
not insignificant risk of sedation and endoscopy, the benefits appear to outweigh 
the risks.  
Timing of screening for esophageal varices appears most prudent in the 
second trimester, after organogenesis is complete in the first trimester and before 
the greatest risk of bleeding at delivery. Despite acceptance of band ligation and 
beta-blockers as firstline management of esophageal varices for non-pregnant 
patients, there are limited data on their efficacy and safety in pregnancy . 
Propranolol is a pregnancy category C drug, but has been used to treat fetal 
arrhythmias as well as maternal conditions such as thyrotoxicosis, arrhythmias, or 
hypertension.  
There are risks of intra uterine growth retardation, neonatal bradycardia, and 
hypoglycemia, but propranolol appears overall to be safe in pregnant patients. 
Traditionally, vaginal delivery with a short second stage of labour with forceps. 
Cesarean sections may be required only for obstetric indications, but carries an 
increased risk of bleeding complications from the surgical site in the setting of 
portal hypertension.  
 
 
WILSON DISEASE (1 in 30,000 to 1 in 1,00,000) 
Wilson disease lead to reduced fertility as copper deposition in the uterus 
may interfere with embryo implantation leading to an increase in miscarriages and 
spontaneous abortions . Pregnancy in general does not appear to change the course 
of Wilson disease  progression 
Pregnancy in general does not appear to change the course of WD 
progression . However, treatment discontinuation or a lack of treatment has been 
reported to lead to disease flares with attendant risk of hepatic decompensation or 
liver failure. There is one recent systematic review on the treatment of WD in 
general, but no reports specific to treatment for WD during pregnancy  Practice 
guidelines for WD recommends continuing treatment during pregnancy, but 
reducing penicillamine or trientine doses by 25–50% to promote wound healing in 
the event that a cesarean section is needed . There is inadequate data to make 
recommendations on a preferred treatment for WD during pregnancy, between 
penicillamine, trientine, or zinc. Some data on conversion to zinc therapy during 
pregnancy has also been reported .  
There are also multiple case reports of fetal myelosuppression or 
embryopathy associated with penicillamine treatment during pregnancy for Wilson 
disease. On the other hand, treatment discontinuation or lack of treatment for WD 
can not only lead to maternal hepatic decompensation but can also lead to copper 
deposition in the placenta and fetal liver, damaging the fetus along with recognized 
risks of maternal hepatic decompensation. Th e risks of treatment discontinuation 
or lack of treatment for WD during pregnancy appears to outweigh the potential 
risks of treatment. The data to recommended dose reduction of penicillamine in 
anticipation of possible caesarean section appears to be very limited. 
 
 
AUTOIMMUNE LIVER DISEASE (1 in 1000 to 1 in 10,000) 
Autoimmune diseases of all types including autoimmune hepatitis are more 
common in women then in men. In women, classic (type 1) autoimmune hepatitis 
typically presents around the expected time of menarche but is associated with 
amenorrhea. 
Immunosuppressive therapy is highly effective in controlling the disease in 
most patients; treated women who subsequently conceive a child should continue 
taking immunosuppressive medications during pregnancy. The doses of 
azathioprine prescribed as part of standard treatment regimens are belived not to be 
teratogenic. 
Occasionally autoimmune liver disease will worsen during the postpartum 
period when the physiologic immunosuppression of pregnancy resolves. For this 
reason affected patients should have frequent measurements of serum 
aminotransferase levels for approximately 6 months after delivery. 
 
Primary biliary cirrhosis  
Older literature suggested poor outcomes of pregnancy in patients with PBC 
. As patients with PBC tend to present at an older age aft er the usual child-bearing 
age, and as women with PBC were discouraged in the past from pursuing 
pregnancy, there is an extremely limited number of studies on PBC and pregnancy. 
However, more recent studies have reported good maternal and fetal outcomes . 
PBC has been associated with disease fl are aft er delivery. UDCA is a pregnancy 
category B drug that is generally recommended for PBC .  
Studies on the use of UDCA treatment for PBC during pregnancy have been 
limited, especially in the fi rst trimester. Similar to the situation with AIH, the 
potential risks of UDCA during pregnancy appear small compared with the 
potential positive effect of treatment on maternal and fetal outcomes. With 
growing evidence that UDCA is safe during pregnancy in other diseases such as 
intrahepatic  cholestasis of pregnancy, and the unlikely scenario that large scale 
studies will be performed on the efficacy and safety of UDCA during pregnancy 
for PBC, it appears prudent to recommend continuation of UDCA for PBC during 
pregnancy at this time 
 
 
 
 
 
  
 
 
 
 
MATERIALS AND METHODS 
 
 
 
 
 
 Study design  
The study was a single institution prospective randomized study conducted 
in Madurai Medical College over a period of six months. 
A total of 40 patients were included in the study. All  the patients were 
thoroughly examined and case sheets were written in the same fashion to facilitate 
comparison. 
All of them underwent clinical examination and an algorithm of 
investigations required to approach the diagnosis of non infective jaundice. 
The patients were subjected to various forms of treatment available in the 
tertiary care centre. 
The protocol was approved by the Ethical Review Board of the institute and 
an informed consent was obtained from all patients. 
PARTICIPANTS  
The patients were selected from those attending the obstetric department at 
the hospital with no specific limitation imposed on age and gestational age. 
All the patients were diagnosed to have jaundice clinically with the 
exclusion criteria being infective hepatitis in pregnancy. 
METHODS 
All the patients satisfying the inclusion criteria were carefully evaluated in 
terms of clinical examination, recording of BP, obstetric examination, laboratory 
investigations including Hb, platelet,  urine albumin, clotting time, renal function 
test, liver function test, serum uric acid, LDH, viral markers, ultrasonogram. 
The patients were followed through the course of the disease taking into 
account the complications of the disease, the management protocols including the 
obstetric management and blood product transfusion, the maternal and fetal 
outcomes and the recovery time. 
The maternal outcome was derived from the rate of complications, ICU stay, 
recovery interval and maternal mortality. 
The fetal outcome was studied by the number of live births, NICU admission 
and perinatal mortality. 
The patients were followed up for the duration of hospital stay and the 
recovery time was recorded.   
 
                        
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
STATISTICS 
 
 
 
 
 
 Tables 
 
 
 
Gravida Total 
Multi Primi 
Count Col % 
Count Col % Count 
Col % 
 
 
Diagnosis 
AFLP 0 .0% 3 12.0% 3 7.5% 
Cirrhosis 2 13.3% 1 4.0% 3 7.5% 
CRIGGLER NAJAR SYN 0 .0% 1 4.0% 1 2.5% 
Hellp 7 46.7% 7 28.0% 14 35.0% 
Partial hellp 6 40.0% 13 52.0% 19 47.5% 
Diagnosis 
Hellp 13 86.7% 20 80.0% 33 82.5% 
Non-Hellp 2 13.3% 5 20.0% 7 17.5% 
Total 15 100.0% 25 100.0% 40 100.0% 
 
Diagnosis * Gravida 
Chi-Square Tests 
 
 
Value df Asymp. Sig. (2-sided) 
Pearson Chi-Square 4.706(a) 4 .319 
Likelihood Ratio 5.999 4 .199 
Linear-by-Linear Association .054 1 .816 
N of Valid Cases 40   
a 6 cells (60.0%) have expected count less than 5. The minimum expected count is .38. 
 
 
Diagnosis * Gravida 
Chi-Square Tests 
 
 
Value df Asymp. Sig. (2-sided) Exact Sig. (2-sided) Exact Sig. (1-sided) 
Pearson Chi-Square .289(b) 1 .591   
Continuity Correction(a) .012 1 .914   
Likelihood Ratio .298 1 .585   
Fisher's Exact Test    .691 .467 
Linear-by-Linear Association .281 1 .596   
N of Valid Cases 40     
a Computed only for a 2x2 table 
b 2 cells (50.0%) have expected count less than 5. The minimum expected count is 2.63. 
 
 
 
Gravida 
Statistical inference 
Multi Primi Total 
Diagnosis        
AFLP 0 .0% 3 12.0% 3 7.5% 
X2=4.706 Df=4 
.319>0.05 Not Significant 
Cirrhosis 2 13.3% 1 4.0% 3 7.5% 
CRIGGLER NAJAR SYN 0 .0% 1 4.0% 1 2.5% 
Hellp 7 46.7% 7 28.0% 14 35.0% 
Partial hellp 6 40.0% 13 52.0% 19 47.5% 
Diagnosis        
Hellp 13 86.7% 20 80.0% 33 82.5% X2=.289 Df=1 
.591>0.05 Not Significant Non-Hellp 2 13.3% 5 20.0% 7 17.5% 
Total 15 100.0% 25 100.0% 40 100.0%  
 
 
 
Tables 
  
 
Complication Total 
Absent Present 
Count Col % 
Count Col % Count 
Col % 
 
 
BP 
Below 130/90 13 50.0% 2 14.3% 15 37.5% 
Above 130/90 13 50.0% 12 85.7% 25 62.5% 
Total 26 100.0% 14 100.0% 40 100.0% 
 
Crosstabs 
Chi-Square Tests 
 
 
Value Df Asymp. Sig. (2-sided) Exact Sig. (2-sided) Exact Sig. (1-sided) 
Pearson Chi-Square 4.952(b) 1 .026   
Continuity Correction(a) 3.546 1 .060   
Likelihood Ratio 5.398 1 .020   
Fisher's Exact Test    .040 .027 
Linear-by-Linear Association 4.829 1 .028   
N of Valid Cases 40     
a Computed only for a 2x2 table 
b 0 cells (.0%) have expected count less than 5. The minimum expected count is 5.25. 
 
 
 
 
 
 
 
 
  
 
Table No – 1  
Tables 
 
Complication 
Statistical inference 
Absent Present Total 
BP        
Below 130/90 13 50.0% 2 14.3% 15 37.5% X2=4.952 Df=1 
.026<0.05 Significant Above 130/90 13 50.0% 12 85.7% 25 62.5% 
Total 26 100.0% 14 100.0% 40 100.0%  
 
 
Diagrams No – 1  
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Below 130/90 Above 130/90 Total
T-Test 
Group Statistics 
 
 
Complication N Mean Std. Deviation Std. Error Mean 
Bilirubin 
Absent 26 2.5462 1.35506 .26575 
Present 14 4.1643 2.51323 .67169 
 
 
 
Independent Samples Test 
 
 
Levene's Test for 
Equality of Variances 
t-test for Equality of Means 
F Sig. T df 
Sig. (2-
tailed) 
Mean 
Difference 
Std. Error 
Difference 
95% Confidence Interval of 
the Difference 
Lower Upper 
Bilirubin 
Equal variances 
assumed 
3.016 .091 
-
2.659 
38 .011 -1.6181 .60844 -2.84986 -.38640 
Equal variances 
not assumed 
 
  
-
2.240 
17.170 .039 -1.6181 .72235 -3.14101 -.09525 
Table No – 2 
T-Test 
Complication N Mean Std. Deviation Statistical inference 
Bilirubin     
Absent 26 2.5462 1.35506 T=-2.659 Df=38 .011<0.05 Significant 
Present 14 4.1643 2.51323  
 
 
 
 
 
 
 
Diagrams No –  2 
 
T-Test 
Group Statistics 
 
 
Complication N Mean Std. Deviation Std. Error Mean 
HB 
Absent 26 8.0077 1.06393 .20865 
Present 14 7.3571 .93126 .24889 
 
Independent Samples Test 
 
 
Levene's Test for 
Equality of Variances 
t-test for Equality of Means 
F Sig. t df 
Sig. (2-
tailed) 
Mean 
Difference 
Std. Error 
Difference 
95% Confidence Interval of 
the Difference 
Lower Upper 
HB 
Equal variances 
assumed 
.196 .660 1.923 38 .062 .6505 .33829 -.03428 1.33538 
Equal variances 
not assumed 
  2.003 29.991 .054 .6505 .32478 -.01275 1.31385 
 
 
26
14
2.5462
4.1643
1.35506
2.51323
0
5
10
15
20
25
30
N Mean Std. Deviation
Bilirubin Absent Present
Complication N Mean Std. Deviation Statistical inference 
HB     
Absent 26 8.0077 1.06393 T=1.923 Df=38 .062>0.05  
Not Significant Present 14 7.3571 .93126 
 
Tables 
 
 
 
Complication Total 
Absent Present 
Count Col % 
Count Col % Count 
Col % 
 
 
Pre Eclamptic features 
Absent 0 .0% 2 14.3% 2 5.0% 
Present 26 100.0% 12 85.7% 38 95.0% 
Total 26 100.0% 14 100.0% 40 100.0% 
 
 
Crosstabs 
Chi-Square Tests 
 
 
Value Df Asymp. Sig. (2-sided) Exact Sig. (2-sided) Exact Sig. (1-sided) 
Pearson Chi-Square 3.910(b) 1 .048   
Continuity Correction(a) 1.481 1 .224   
Likelihood Ratio 4.398 1 .036   
Fisher's Exact Test    .117 .117 
Linear-by-Linear Association 3.812 1 .051   
N of Valid Cases 40     
a Computed only for a 2x2 table 
b 2 cells (50.0%) have expected count less than 5. The minimum expected count is .70. 
 
Table No – 3 
Tables 
 
Complication 
Statistical inference 
Absent Present Total 
Pre Eclamptic features        
Absent 0 .0% 2 14.3% 2 5.0% X2=3.910 Df=1  
.048<0.05 Significant Present 26 100.0% 12 85.7% 38 95.0% 
Total 26 100.0% 14 100.0% 40 100.0%  
 
 
Diagrams No – 3 
 
 
 
 
Tables 
 
 
 
Complication Total 
Absent Present Count Col % 
0
26 26
2
12
14
2
38
40
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10
15
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35
40
1 2 3
Absent Present Total
Count Col % Count 
Col % 
 
 
Diagnosis Delivery intervel 
<24 21 80.8% 4 28.6% 25 62.5% 
>24 5 19.2% 10 71.4% 15 37.5% 
Total 26 100.0% 14 100.0% 40 100.0% 
 
Chi-Square Tests 
 
 
Value Df Asymp. Sig. (2-sided) Exact Sig. (2-sided) Exact Sig. (1-sided) 
Pearson Chi-Square 10.579(b) 1 .001   
Continuity Correction(a) 8.469 1 .004   
Likelihood Ratio 10.717 1 .001   
Fisher's Exact Test    .002 .002 
Linear-by-Linear Association 10.314 1 .001   
N of Valid Cases 40     
a Computed only for a 2x2 table 
b 0 cells (.0%) have expected count less than 5. The minimum expected count is 5.25. 
 
 
 
 
Table No – 4 
Tables 
 
Complication 
Statistical inference 
Absent Present Total 
Diagnosis Delivery intervel        
<24 21 80.8% 4 28.6% 25 62.5% X2=10.579 Df=1  
.001<0.05 Significant >24 5 19.2% 10 71.4% 15 37.5% 
Total 26 100.0% 14 100.0% 40 100.0%  
 
Diagrams No – 4 
 
 
 
 
 
Tables 
 
 
 
Gravida Total 
Multi Primi 
Count Col % 
Count Col % Count 
Col % 
 
 
Maternal Mortality 
Absent 13 86.7% 24 96.0% 37 92.5% 
Present 2 13.3% 1 4.0% 3 7.5% 
Total 15 100.0% 25 100.0% 40 100.0% 
 
21
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1 2 3
<24 >24 Total
Maternal Mortality * Gravida 
Chi-Square Tests 
 
 
Value Df Asymp. Sig. (2-sided) Exact Sig. (2-sided) Exact Sig. (1-sided) 
Pearson Chi-Square 1.177(b) 1 .278   
Continuity Correction(a) .216 1 .642   
Likelihood Ratio 1.133 1 .287   
Fisher's Exact Test    .545 .312 
Linear-by-Linear Association 1.148 1 .284   
N of Valid Cases 40     
a Computed only for a 2x2 table 
b 2 cells (50.0%) have expected count less than 5. The minimum expected count is 1.13. 
 
 
 
 
 
Table No – 5 
Tables 
 
Gravida 
Statistical inference 
Multi Primi Total 
Maternal Mortality        
Absent 13 86.7% 24 96.0% 37 92.5% X2=5.177 Df=1  
.027<0.05 Significant Present 2 13.3% 1 4.0% 3 7.5% 
Total 15 100.0% 25 100.0% 40 100.0%  
 
 
 
 
 
 
Diagrams No – 5 
 
 
 
 
 
 
Tables 
 
 
 
Delivery recovery time Total 
NA <7 days Above 7days 
Count Col % 
Count Col % Count Col % Count 
Col % 
 
 
BP 
Below 130/90 1 16.7% 10 55.6% 4 25.0% 15 37.5% 
Above 130/90 5 83.3% 8 44.4% 12 75.0% 25 62.5% 
Total 6 100.0% 18 100.0% 16 100.0% 40 100.0% 
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Absent Present
Crosstabs 
Chi-Square Tests 
 
 
Value df Asymp. Sig. (2-sided) 
Pearson Chi-Square 4.681(a) 2 .096 
Likelihood Ratio 4.793 2 .091 
Linear-by-Linear Association .120 1 .729 
N of Valid Cases 40   
a 2 cells (33.3%) have expected count less than 5. The minimum expected count is 2.25. 
Table No – 6 
Tables 
 
Delivery recovery time 
Statistical inference 
NA <7 days Above 7days Total 
BP          
Below 130/90 1 16.7% 10 55.6% 4 25.0% 15 37.5% 
X2=6.681 Df=2 .017<0.05 Significant 
Above 130/90 5 83.3% 8 44.4% 12 75.0% 25 62.5% 
Total 6 100.0% 18 100.0% 16 100.0% 40 100.0%  
 
\Diagrams No – 6 
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 Tables 
 
 
 
NICU Total 
NA NICU No NICU 
Count Col % 
Count Col % Count Col % Count 
Col % 
 
 
Gestational age 
<37 5 55.6% 19 70.4% 4 100.0% 28 70.0% 
>37 4 44.4% 8 29.6% 0 .0% 12 30.0% 
Total 9 100.0% 27 100.0% 4 100.0% 40 100.0% 
 
 
 
 
Crosstabs 
Chi-Square Tests 
 
 
Value df Asymp. Sig. (2-sided) 
Pearson Chi-Square 2.610(a) 2 .271 
Likelihood Ratio 3.688 2 .158 
Linear-by-Linear Association 2.345 1 .126 
N of Valid Cases 40   
a 3 cells (50.0%) have expected count less than 5. The minimum expected count is 1.20. 
 
Table No – 7 
 
 
 
 
 
Tables 
 
NICU 
Statistical inference 
NA NICU No NICU Total 
Gestational age          
<37 5 55.6% 19 70.4% 4 100.0% 28 70.0% 
X2=8.932 Df=2 .027<0.05 Significant 
>37 4 44.4% 8 29.6% 0 .0% 12 30.0% 
Total 9 100.0% 27 100.0% 4 100.0% 40 100.0%  
 
Diagrams No – 7 
 
Frequency Table 
Age 
 
 
Frequency Percent Valid Percent Cumulative Percent 
Valid 
22 5 12.5 12.5 12.5 
23 2 5.0 5.0 17.5 
24 4 10.0 10.0 27.5 
25 3 7.5 7.5 35.0 
26 6 15.0 15.0 50.0 
27 7 17.5 17.5 67.5 
28 2 5.0 5.0 72.5 
5
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1 2 3 4
<37 >37 Total
29 1 2.5 2.5 75.0 
30 4 10.0 10.0 85.0 
31 1 2.5 2.5 87.5 
32 2 5.0 5.0 92.5 
33 2 5.0 5.0 97.5 
34 1 2.5 2.5 100.0 
Total 40 100.0 100.0  
Frequency Table 
Age 
Particulars 
No.of respondents 
(n=40) 
Percentage 
(100%) 
22 5 12.5 
23 2 5.0 
24 4 10.0 
25 3 7.5 
26 6 15.0 
27 7 17.5 
28 2 5.0 
29 1 2.5 
30 4 10.0 
31 1 2.5 
32 2 5.0 
33 2 5.0 
34 1 2.5 
 
Frequency Table 
 
 
 
 
 
Table No – 8 
Age 
Particulars 
No.of respondents 
(n=40) 
Percentage 
(100%) 
Below 25yrs 14 35.0 
26 to 30yrs 20 50.0 
above 31yrs 6 15.0 
 
 
Diagrams No – 8 
 
Age 
 
 
Frequency Percent Valid Percent Cumulative Percent 
Valid 
Below 25yrs 14 35.0 35.0 35.0 
26 to 30yrs 20 50.0 50.0 85.0 
above 31yrs 6 15.0 15.0 100.0 
Total 40 100.0 100.0  
 
 
14
20
6
0
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Below 25yrs 26 to 30yrs above 31yrs
Gravida 
 
 
Frequency Percent Valid Percent Cumulative Percent 
Valid 
Multi 15 37.5 37.5 37.5 
Primi 25 62.5 62.5 100.0 
Total 40 100.0 100.0  
 
Table No – 9 
Gravida 
Particulars 
No.of respondents 
(n=40) 
Percentage 
(100%) 
Multi 15 37.5 
Primi 25 62.5 
 
 
Diagrams No – 9 
 
 
 
Multi, 15
Primi, 25
Multi Primi
Gestational age <37 
 
 
Frequency Percent Valid Percent Cumulative Percent 
Valid 
No 12 30.0 30.0 30.0 
Yes 28 70.0 70.0 100.0 
Total 40 100.0 100.0  
 
Table No – 10 
Gestational age <37 
Particulars 
No.of respondents 
(n=40) 
Percentage 
(100%) 
No 12 30.0 
Yes 28 70.0 
 
 
 
 
Diagrams No – 10 
 
 
No, 12
Yes, 28
No Yes
Gestational age >37 
 
 
Frequency Percent Valid Percent Cumulative Percent 
Valid 
No 28 70.0 70.0 70.0 
Yes 12 30.0 30.0 100.0 
Total 40 100.0 100.0  
 
Table No – 11 
Gestational age >37 
Particulars 
No.of respondents 
(n=40) 
Percentage 
(100%) 
No 28 70.0 
Yes 12 30.0 
 
 
 
Diagrams No – 11 
 
 
No, 28
Yes, 12
No Yes
Gestational age 
 
 
Frequency Percent Valid Percent Cumulative Percent 
Valid 
<37 28 70.0 70.0 70.0 
>37 12 30.0 30.0 100.0 
Total 40 100.0 100.0  
 
Table No – 12 
Gestational age 
Particulars 
No.of respondents 
(n=40) 
Percentage 
(100%) 
<37 28 70.0 
>37 12 30.0 
 
Diagrams No – 12 
 
BP1 
 
 
Frequency Percent Valid Percent Cumulative Percent 
Valid 
110 4 10.0 10.0 10.0 
120 6 15.0 15.0 25.0 
<37, 28
>37, 12
<37 >37
130 6 15.0 15.0 40.0 
140 9 22.5 22.5 62.5 
150 5 12.5 12.5 75.0 
160 10 25.0 25.0 100.0 
Total 40 100.0 100.0  
 
 
BP1 
Particulars 
No.of respondents 
(n=40) 
Percentage 
(100%) 
110 4 10.0 
120 6 15.0 
130 6 15.0 
140 9 22.5 
150 5 12.5 
160 10 25.0 
 
BP2 
 
 
Frequency Percent Valid Percent Cumulative Percent 
Valid 
70 3 7.5 7.5 7.5 
80 2 5.0 5.0 12.5 
90 27 67.5 67.5 80.0 
100 8 20.0 20.0 100.0 
Total 40 100.0 100.0  
 
 
 
 
 
 BP2 
Particulars 
No.of respondents 
(n=40) 
Percentage 
(100%) 
70 3 7.5 
80 2 5.0 
90 27 67.5 
100 8 20.0 
 
 
 
 
BP 
 
 
Frequency Percent Valid Percent Cumulative Percent 
Valid 
110/70 3 7.5 7.5 7.5 
110/80 1 2.5 2.5 10.0 
120/90 6 15.0 15.0 25.0 
130/100 1 2.5 2.5 27.5 
130/80 1 2.5 2.5 30.0 
130/90 4 10.0 10.0 40.0 
140/90 9 22.5 22.5 62.5 
150/100 1 2.5 2.5 65.0 
150/90 4 10.0 10.0 75.0 
160/100 8 20.0 20.0 95.0 
160/90 2 5.0 5.0 100.0 
Total 40 100.0 100.0  
 
BP 
Particulars 
No.of respondents 
(n=40) 
Percentage 
(100%) 
110/70 3 7.5 
110/80 1 2.5 
120/90 6 15.0 
130/100 1 2.5 
130/80 1 2.5 
130/90 4 10.0 
140/90 9 22.5 
150/100 1 2.5 
150/90 4 10.0 
160/100 8 20.0 
160/90 2 5.0 
 
BP 
 
 
Frequency Percent Valid Percent Cumulative Percent 
Valid 
Below 130/90 15 37.5 37.5 37.5 
Above 130/90 25 62.5 62.5 100.0 
Total 40 100.0 100.0  
 
Table No – 13 
BP 
Particulars 
No.of respondents 
(n=40) 
Percentage 
(100%) 
Below 130/90 15 37.5 
Above 130/90 25 62.5 
 
Diagrams No – 13 
 Pedal edema 
 
 
Frequency Percent Valid Percent Cumulative Percent 
Valid 
Absent 5 12.5 12.5 12.5 
Present 35 87.5 87.5 100.0 
Total 40 100.0 100.0  
 
Pedal edema 
Particulars 
No.of respondents 
(n=40) 
Percentage 
(100%) 
Absent 5 12.5 
Present 35 87.5 
 
 
Icteric 
 
 
Frequency Percent Valid Percent Cumulative Percent 
Valid Present 40 100.0 100.0 100.0 
 
 
 
 
Below 130/90, 15
Above 130/90, 25
Below 130/90 Above 130/90
Icteric 
Particulars 
No.of respondents 
(n=40) 
Percentage 
(100%) 
Present 40 100.0 
 
 
Fever 
 
 
Frequency Percent Valid Percent Cumulative Percent 
Valid 
Absent 34 85.0 85.0 85.0 
Present 6 15.0 15.0 100.0 
Total 40 100.0 100.0  
Fever 
Particulars 
No.of respondents 
(n=40) 
Percentage 
(100%) 
Absent 34 85.0 
Present 6 15.0 
 
Pruritis 
 
 
Frequency Percent Valid Percent Cumulative Percent 
Valid 
Absent 33 82.5 82.5 82.5 
Present 7 17.5 17.5 100.0 
Total 40 100.0 100.0  
 
Pruritis 
Particulars 
No.of respondents 
(n=40) 
Percentage 
(100%) 
Absent 33 82.5 
Present 7 17.5 
 
ganomegaly 
 
 
Frequency Percent Valid Percent Cumulative Percent 
Valid 
Absent 29 72.5 72.5 72.5 
Present 11 27.5 27.5 100.0 
Total 40 100.0 100.0  
 
Organomegaly 
Particulars 
No.of respondents 
(n=40) 
Percentage 
(100%) 
Absent 29 72.5 
Present 11 27.5 
 
Pre Eclamptic features 
 
 
Frequency Percent Valid Percent Cumulative Percent 
Valid 
Absent 2 5.0 5.0 5.0 
Present 38 95.0 95.0 100.0 
Total 40 100.0 100.0  
 
Pre Eclamptic features 
Particulars 
No.of respondents 
(n=40) 
Percentage 
(100%) 
Absent 2 5.0 
Present 38 95.0 
 
 
 
 
 
USG 
 
 
Frequency Percent Valid Percent Cumulative Percent 
Valid 
cirrhosis with PHT. 2 5.0 5.0 5.0 
cirrhosis with PHT,spleenic vein dilated 2 5.0 5.0 10.0 
mild fatty changes in liver 3 7.5 7.5 17.5 
mild hepatomegaly 1 2.5 2.5 20.0 
non expanding liver heamatoma ,PHT 1 2.5 2.5 22.5 
Normal 24 60.0 60.0 82.5 
Splenomegaly 7 17.5 17.5 100.0 
Total 40 100.0 100.0  
 
Table No – 14 
USG 
Particulars 
No.of respondents 
(n=40) 
Percentage 
(100%) 
cirrhosis with PHT. 2 5.0 
cirrhosis with PHT,spleenic vein dilated 2 5.0 
mild fatty changes in liver 3 7.5 
mild hepatomegaly 1 2.5 
non expanding liver heamatoma ,PHT 1 2.5 
Normal 24 60.0 
Splenomegaly 7 17.5 
 
 
 
 
 
 
 
 
Diagrams No – 14 
 
HB 
 
 
Frequency Percent Valid Percent Cumulative Percent 
Valid 
6.00 2 5.0 5.0 5.0 
6.20 3 7.5 7.5 12.5 
6.40 1 2.5 2.5 15.0 
6.60 1 2.5 2.5 17.5 
6.70 2 5.0 5.0 22.5 
6.80 2 5.0 5.0 27.5 
7.00 1 2.5 2.5 30.0 
7.20 3 7.5 7.5 37.5 
7.50 1 2.5 2.5 40.0 
7.80 4 10.0 10.0 50.0 
8.00 5 12.5 12.5 62.5 
8.20 1 2.5 2.5 65.0 
8.50 1 2.5 2.5 67.5 
2 2
3
1 1
24
7
0
5
10
15
20
25
cirrhosis with
PHT.
cirrhosis with
PHT,spleenic
vein dilated
mild fatty
changes in liver
mild
hepatomegaly
non expanding
liver heamatoma
,PHT
normal splenomegaly
8.60 1 2.5 2.5 70.0 
8.80 5 12.5 12.5 82.5 
9.00 5 12.5 12.5 95.0 
9.20 1 2.5 2.5 97.5 
9.80 1 2.5 2.5 100.0 
Total 40 100.0 100.0  
 
 
HB 
 
 
Frequency Percent Valid Percent Cumulative Percent 
Valid 
<7 12 30.0 30.0 30.0 
>7 28 70.0 70.0 100.0 
Total 40 100.0 100.0  
 
 
HB 
Particulars 
No.of respondents 
(n=40) 
Percentage 
(100%) 
6.00 2 5.0 
6.20 3 7.5 
6.40 1 2.5 
6.60 1 2.5 
6.70 2 5.0 
6.80 2 5.0 
7.00 1 2.5 
7.20 3 7.5 
7.50 1 2.5 
7.80 4 10.0 
8.00 5 12.5 
8.20 1 2.5 
8.50 1 2.5 
8.60 1 2.5 
8.80 5 12.5 
9.00 5 12.5 
9.20 1 2.5 
9.80 1 2.5 
 
Table No – 15 
HB 
Particulars 
No.of respondents 
(n=40) 
Percentage 
(100%) 
<7 12 30.0 
>7 28 70.0 
 
 
Diagrams No – 15 
  
<7, 12
>7, 28
<7 >7
 Platelet 
 
 
Frequency Percent Valid Percent Cumulative Percent 
Valid 
36000.00 3 7.5 7.5 7.5 
40000.00 3 7.5 7.5 15.0 
43000.00 1 2.5 2.5 17.5 
45000.00 1 2.5 2.5 20.0 
54000.00 1 2.5 2.5 22.5 
56000.00 3 7.5 7.5 30.0 
60000.00 2 5.0 5.0 35.0 
65000.00 2 5.0 5.0 40.0 
67000.00 2 5.0 5.0 45.0 
70000.00 1 2.5 2.5 47.5 
72000.00 2 5.0 5.0 52.5 
74000.00 1 2.5 2.5 55.0 
76000.00 1 2.5 2.5 57.5 
78000.00 1 2.5 2.5 60.0 
80000.00 4 10.0 10.0 70.0 
87000.00 1 2.5 2.5 72.5 
88000.00 1 2.5 2.5 75.0 
90000.00 2 5.0 5.0 80.0 
94000.00 1 2.5 2.5 82.5 
100000.00 1 2.5 2.5 85.0 
110000.00 1 2.5 2.5 87.5 
120000.00 1 2.5 2.5 90.0 
125000.00 1 2.5 2.5 92.5 
150000.00 2 5.0 5.0 97.5 
200000.00 1 2.5 2.5 100.0 
Total 40 100.0 100.0  
 
 
Platelet 
Particulars 
No.of respondents 
(n=40) 
Percentage 
(100%) 
36000.00 3 7.5 
40000.00 3 7.5 
43000.00 1 2.5 
45000.00 1 2.5 
54000.00 1 2.5 
56000.00 3 7.5 
60000.00 2 5.0 
65000.00 2 5.0 
67000.00 2 5.0 
70000.00 1 2.5 
72000.00 2 5.0 
74000.00 1 2.5 
76000.00 1 2.5 
78000.00 1 2.5 
80000.00 4 10.0 
87000.00 1 2.5 
88000.00 1 2.5 
90000.00 2 5.0 
94000.00 1 2.5 
100000.00 1 2.5 
110000.00 1 2.5 
120000.00 1 2.5 
125000.00 1 2.5 
150000.00 2 5.0 
200000.00 1 2.5 
 
 
 
Urine albumin 
 
 
Frequency Percent Valid Percent Cumulative Percent 
Valid 
Absent 3 7.5 7.5 7.5 
Mild 12 30.0 30.0 37.5 
Moderate 16 40.0 40.0 77.5 
Severe 9 22.5 22.5 100.0 
Total 40 100.0 100.0  
 
Urine albumin 
Particulars 
No.of respondents 
(n=40) 
Percentage 
(100%) 
Absent 3 7.5 
Mild 12 30.0 
Moderate 16 40.0 
Severe 9 22.5 
 
Table No – 16 
Urine albumin 
Particulars 
No.of respondents 
(n=40) 
Percentage 
(100%) 
Absent 3 7.5 
Mild 12 30.0 
Moderate 16 40.0 
Severe 9 22.5 
 
 
 Diagrams No – 16 
 
 
 
Urea 
 
 
Frequency Percent Valid Percent Cumulative Percent 
Valid 
24.00 1 2.5 2.5 2.5 
26.00 1 2.5 2.5 5.0 
28.00 2 5.0 5.0 10.0 
30.00 1 2.5 2.5 12.5 
32.00 2 5.0 5.0 17.5 
34.00 5 12.5 12.5 30.0 
36.00 2 5.0 5.0 35.0 
38.00 7 17.5 17.5 52.5 
3
12
16
9
0
2
4
6
8
10
12
14
16
Absent Mild Moderate Severe
40.00 2 5.0 5.0 57.5 
41.00 2 5.0 5.0 62.5 
42.00 5 12.5 12.5 75.0 
43.00 1 2.5 2.5 77.5 
44.00 2 5.0 5.0 82.5 
46.00 2 5.0 5.0 87.5 
48.00 2 5.0 5.0 92.5 
53.00 1 2.5 2.5 95.0 
56.00 1 2.5 2.5 97.5 
73.00 1 2.5 2.5 100.0 
Total 40 100.0 100.0  
 
 
 
 
Urea 
Particulars 
No.of respondents 
(n=40) 
Percentage 
(100%) 
24.00 1 2.5 
26.00 1 2.5 
28.00 2 5.0 
30.00 1 2.5 
32.00 2 5.0 
34.00 5 12.5 
36.00 2 5.0 
38.00 7 17.5 
40.00 2 5.0 
41.00 2 5.0 
42.00 5 12.5 
43.00 1 2.5 
44.00 2 5.0 
46.00 2 5.0 
48.00 2 5.0 
53.00 1 2.5 
56.00 1 2.5 
73.00 1 2.5 
 
 
 
Creatinine 
 
 
Frequency Percent Valid Percent Cumulative Percent 
Valid 
.80 6 15.0 15.0 15.0 
.90 7 17.5 17.5 32.5 
1.00 1 2.5 2.5 35.0 
1.10 2 5.0 5.0 40.0 
1.20 5 12.5 12.5 52.5 
1.30 3 7.5 7.5 60.0 
1.40 3 7.5 7.5 67.5 
1.70 1 2.5 2.5 70.0 
1.80 8 20.0 20.0 90.0 
2.00 1 2.5 2.5 92.5 
2.10 1 2.5 2.5 95.0 
2.20 2 5.0 5.0 100.0 
Total 40 100.0 100.0  
 
 
 
 
\Creatinine 
Particulars 
No.of respondents 
(n=40) 
Percentage 
(100%) 
.80 6 15.0 
.90 7 17.5 
1.00 1 2.5 
1.10 2 5.0 
1.20 5 12.5 
1.30 3 7.5 
1.40 3 7.5 
1.70 1 2.5 
1.80 8 20.0 
2.00 1 2.5 
2.10 1 2.5 
2.20 2 5.0 
 
 
 
Bilirubin 
 
 
Frequency Percent Valid Percent Cumulative Percent 
Valid 
1.40 1 2.5 2.5 2.5 
1.50 1 2.5 2.5 5.0 
1.80 5 12.5 12.5 17.5 
1.90 1 2.5 2.5 20.0 
2.00 1 2.5 2.5 22.5 
2.10 4 10.0 10.0 32.5 
2.20 3 7.5 7.5 40.0 
2.30 3 7.5 7.5 47.5 
2.40 1 2.5 2.5 50.0 
2.60 2 5.0 5.0 55.0 
2.80 1 2.5 2.5 57.5 
3.00 4 10.0 10.0 67.5 
3.10 3 7.5 7.5 75.0 
3.60 4 10.0 10.0 85.0 
4.40 2 5.0 5.0 90.0 
4.50 1 2.5 2.5 92.5 
7.40 1 2.5 2.5 95.0 
8.30 1 2.5 2.5 97.5 
11.70 1 2.5 2.5 100.0 
Total 40 100.0 100.0  
 
Bilirubin 
 
 
Frequency Percent Valid Percent Cumulative Percent 
Valid 
<1.5 2 5.0 5.0 5.0 
>1.5 38 95.0 95.0 100.0 
Total 40 100.0 100.0  
 
Bilirubin 
Particulars 
No.of respondents 
(n=40) 
Percentage 
(100%) 
1.40 1 2.5 
1.50 1 2.5 
1.80 5 12.5 
1.90 1 2.5 
2.00 1 2.5 
2.10 4 10.0 
2.20 3 7.5 
2.30 3 7.5 
2.40 1 2.5 
2.60 2 5.0 
2.80 1 2.5 
3.00 4 10.0 
3.10 3 7.5 
3.60 4 10.0 
4.40 2 5.0 
4.50 1 2.5 
7.40 1 2.5 
8.30 1 2.5 
11.70 1 2.5 
Table No – 17 
Bilirubin 
Particulars 
No.of respondents 
(n=40) 
Percentage 
(100%) 
<1.5 2 5.0 
>1.5 38 95.0 
 
Diagrams No – 17 
  
<1.5, 2
>1.5, 38
<1.5 >1.5
SGPT 
 
 
Frequency Percent Valid Percent Cumulative Percent 
Valid 
56.00 1 2.5 2.5 2.5 
65.00 1 2.5 2.5 5.0 
68.00 1 2.5 2.5 7.5 
72.00 1 2.5 2.5 10.0 
74.00 1 2.5 2.5 12.5 
75.00 1 2.5 2.5 15.0 
78.00 2 5.0 5.0 20.0 
80.00 2 5.0 5.0 25.0 
81.00 1 2.5 2.5 27.5 
85.00 1 2.5 2.5 30.0 
87.00 1 2.5 2.5 32.5 
88.00 1 2.5 2.5 35.0 
89.00 1 2.5 2.5 37.5 
90.00 4 10.0 10.0 47.5 
98.00 1 2.5 2.5 50.0 
102.00 3 7.5 7.5 57.5 
106.00 2 5.0 5.0 62.5 
110.00 2 5.0 5.0 67.5 
121.00 1 2.5 2.5 70.0 
122.00 1 2.5 2.5 72.5 
124.00 1 2.5 2.5 75.0 
130.00 1 2.5 2.5 77.5 
132.00 1 2.5 2.5 80.0 
140.00 2 5.0 5.0 85.0 
143.00 1 2.5 2.5 87.5 
170.00 1 2.5 2.5 90.0 
206.00 1 2.5 2.5 92.5 
207.00 1 2.5 2.5 95.0 
226.00 1 2.5 2.5 97.5 
253.00 1 2.5 2.5 100.0 
Total 40 100.0 100.0  
 
SGPT 
Particulars 
No.of respondents 
(n=40) 
Percentage 
(100%) 
56.00 1 2.5 
65.00 1 2.5 
68.00 1 2.5 
72.00 1 2.5 
74.00 1 2.5 
75.00 1 2.5 
78.00 2 5.0 
80.00 2 5.0 
81.00 1 2.5 
85.00 1 2.5 
87.00 1 2.5 
88.00 1 2.5 
89.00 1 2.5 
90.00 4 10.0 
98.00 1 2.5 
102.00 3 7.5 
106.00 2 5.0 
110.00 2 5.0 
121.00 1 2.5 
122.00 1 2.5 
124.00 1 2.5 
130.00 1 2.5 
132.00 1 2.5 
140.00 2 5.0 
143.00 1 2.5 
170.00 1 2.5 
206.00 1 2.5 
207.00 1 2.5 
226.00 1 2.5 
253.00 1 2.5 
 
SGOT 
 
 
Frequency Percent Valid Percent Cumulative Percent 
Valid 
60.00 1 2.5 2.5 2.5 
65.00 1 2.5 2.5 5.0 
68.00 1 2.5 2.5 7.5 
78.00 1 2.5 2.5 10.0 
80.00 1 2.5 2.5 12.5 
84.00 1 2.5 2.5 15.0 
85.00 1 2.5 2.5 17.5 
86.00 1 2.5 2.5 20.0 
88.00 2 5.0 5.0 25.0 
89.00 1 2.5 2.5 27.5 
94.00 2 5.0 5.0 32.5 
98.00 4 10.0 10.0 42.5 
101.00 1 2.5 2.5 45.0 
102.00 2 5.0 5.0 50.0 
108.00 1 2.5 2.5 52.5 
124.00 1 2.5 2.5 55.0 
126.00 1 2.5 2.5 57.5 
130.00 1 2.5 2.5 60.0 
134.00 1 2.5 2.5 62.5 
140.00 6 15.0 15.0 77.5 
164.00 1 2.5 2.5 80.0 
168.00 1 2.5 2.5 82.5 
178.00 2 5.0 5.0 87.5 
188.00 1 2.5 2.5 90.0 
228.00 1 2.5 2.5 92.5 
240.00 1 2.5 2.5 95.0 
246.00 1 2.5 2.5 97.5 
278.00 1 2.5 2.5 100.0 
Total 40 100.0 100.0  
 
 
 
 
 
SGOT 
Particulars 
No.of respondents 
(n=40) 
Percentage 
(100%) 
60.00 1 2.5 
65.00 1 2.5 
68.00 1 2.5 
78.00 1 2.5 
80.00 1 2.5 
84.00 1 2.5 
85.00 1 2.5 
86.00 1 2.5 
88.00 2 5.0 
89.00 1 2.5 
94.00 2 5.0 
98.00 4 10.0 
101.00 1 2.5 
102.00 2 5.0 
108.00 1 2.5 
124.00 1 2.5 
126.00 1 2.5 
130.00 1 2.5 
134.00 1 2.5 
140.00 6 15.0 
164.00 1 2.5 
168.00 1 2.5 
178.00 2 5.0 
188.00 1 2.5 
228.00 1 2.5 
240.00 1 2.5 
246.00 1 2.5 
278.00 1 2.5 
 
RBS 
 
 
Frequency Percent Valid Percent Cumulative Percent 
Valid 
60.00 1 2.5 2.5 2.5 
62.00 1 2.5 2.5 5.0 
64.00 2 5.0 5.0 10.0 
80.00 1 2.5 2.5 12.5 
85.00 1 2.5 2.5 15.0 
90.00 6 15.0 15.0 30.0 
95.00 1 2.5 2.5 32.5 
100.00 2 5.0 5.0 37.5 
101.00 1 2.5 2.5 40.0 
107.00 1 2.5 2.5 42.5 
110.00 3 7.5 7.5 50.0 
122.00 1 2.5 2.5 52.5 
124.00 2 5.0 5.0 57.5 
126.00 1 2.5 2.5 60.0 
127.00 1 2.5 2.5 62.5 
130.00 5 12.5 12.5 75.0 
135.00 1 2.5 2.5 77.5 
136.00 1 2.5 2.5 80.0 
137.00 1 2.5 2.5 82.5 
140.00 2 5.0 5.0 87.5 
150.00 1 2.5 2.5 90.0 
160.00 2 5.0 5.0 95.0 
250.00 2 5.0 5.0 100.0 
Total 40 100.0 100.0  
 
RBS 
Particulars 
No.of respondents 
(n=40) 
Percentage 
(100%) 
60.00 1 2.5 
62.00 1 2.5 
64.00 2 5.0 
80.00 1 2.5 
85.00 1 2.5 
90.00 6 15.0 
95.00 1 2.5 
100.00 2 5.0 
101.00 1 2.5 
107.00 1 2.5 
110.00 3 7.5 
122.00 1 2.5 
124.00 2 5.0 
126.00 1 2.5 
127.00 1 2.5 
130.00 5 12.5 
135.00 1 2.5 
136.00 1 2.5 
137.00 1 2.5 
140.00 2 5.0 
150.00 1 2.5 
160.00 2 5.0 
250.00 2 5.0 
 
LDH 
 
 
Frequency Percent Valid Percent Cumulative Percent 
Valid 
300.00 1 2.5 2.5 2.5 
410.00 6 15.0 15.0 17.5 
412.00 1 2.5 2.5 20.0 
420.00 3 7.5 7.5 27.5 
422.00 1 2.5 2.5 30.0 
424.00 1 2.5 2.5 32.5 
440.00 1 2.5 2.5 35.0 
445.00 1 2.5 2.5 37.5 
447.00 1 2.5 2.5 40.0 
450.00 2 5.0 5.0 45.0 
460.00 2 5.0 5.0 50.0 
464.00 1 2.5 2.5 52.5 
470.00 2 5.0 5.0 57.5 
490.00 1 2.5 2.5 60.0 
510.00 2 5.0 5.0 65.0 
520.00 2 5.0 5.0 70.0 
521.00 1 2.5 2.5 72.5 
526.00 1 2.5 2.5 75.0 
540.00 1 2.5 2.5 77.5 
550.00 2 5.0 5.0 82.5 
570.00 1 2.5 2.5 85.0 
600.00 1 2.5 2.5 87.5 
640.00 1 2.5 2.5 90.0 
650.00 1 2.5 2.5 92.5 
653.00 1 2.5 2.5 95.0 
700.00 1 2.5 2.5 97.5 
830.00 1 2.5 2.5 100.0 
Total 40 100.0 100.0  
 
  
 
 
 
 LDH 
Particulars 
No.of respondents 
(n=40) 
Percentage 
(100%) 
300.00 1 2.5 
410.00 6 15.0 
412.00 1 2.5 
420.00 3 7.5 
422.00 1 2.5 
424.00 1 2.5 
440.00 1 2.5 
445.00 1 2.5 
447.00 1 2.5 
450.00 2 5.0 
460.00 2 5.0 
464.00 1 2.5 
470.00 2 5.0 
490.00 1 2.5 
510.00 2 5.0 
520.00 2 5.0 
521.00 1 2.5 
526.00 1 2.5 
540.00 1 2.5 
550.00 2 5.0 
570.00 1 2.5 
600.00 1 2.5 
640.00 1 2.5 
650.00 1 2.5 
653.00 1 2.5 
700.00 1 2.5 
830.00 1 2.5 
 
 
Clotting time 
 
 
Frequency Percent Valid Percent Cumulative Percent 
Valid 
3 2 5.0 5.0 5.0 
4 12 30.0 30.0 35.0 
5 9 22.5 22.5 57.5 
6 5 12.5 12.5 70.0 
7 6 15.0 15.0 85.0 
8 2 5.0 5.0 90.0 
10 2 5.0 5.0 95.0 
12 1 2.5 2.5 97.5 
14 1 2.5 2.5 100.0 
Total 40 100.0 100.0  
 
4 
 
 
 
 
Clotting time 
 
 
Frequency Percent Valid Percent Cumulative Percent 
Valid 
<7 34 85.0 85.0 85.0 
>7 6 15.0 15.0 100.0 
Total 40 100.0 100.0  
 
 
 
 
Clotting time 
Particulars 
No.of respondents 
(n=40) 
Percentage 
(100%) 
3 2 5.0 
4 12 30.0 
5 9 22.5 
6 5 12.5 
7 6 15.0 
8 2 5.0 
10 2 5.0 
12 1 2.5 
14 1 2.5 
 
Table No – 18 
Clotting time 
Particulars 
No.of respondents 
(n=40) 
Percentage 
(100%) 
<7 34 85.0 
>7 6 15.0 
 
Diagrams No – 18 
 
 
<7, 34
>7, 6
<7 >7
  
Blood transfusion (WBBlood transfusion) 
 
 
Frequency Percent Valid Percent Cumulative Percent 
Valid 
.00 5 12.5 12.5 12.5 
1.00 4 10.0 10.0 22.5 
2.00 14 35.0 35.0 57.5 
3.00 5 12.5 12.5 70.0 
4.00 11 27.5 27.5 97.5 
6.00 1 2.5 2.5 100.0 
Total 40 100.0 100.0  
 
 
Blood transfusion (WBBlood transfusion) 
 
Particulars 
No.of respondents 
(n=40) 
Percentage 
(100%) 
.00 5 12.5 
1.00 4 10.0 
2.00 14 35.0 
3.00 5 12.5 
4.00 11 27.5 
6.00 1 2.5 
 
Blood transfusion (FFPBlood transfusion) 
 
 
Frequency Percent Valid Percent Cumulative Percent 
Valid .00 3 7.5 7.5 7.5 
1.00 8 20.0 20.0 27.5 
2.00 13 32.5 32.5 60.0 
3.00 1 2.5 2.5 62.5 
4.00 7 17.5 17.5 80.0 
5.00 1 2.5 2.5 82.5 
6.00 5 12.5 12.5 95.0 
8.00 1 2.5 2.5 97.5 
14.00 1 2.5 2.5 100.0 
Total 40 100.0 100.0  
 
Blood transfusion (FFPBlood transfusion) 
Particulars 
No.of respondents 
(n=40) 
Percentage 
(100%) 
.00 3 7.5 
1.00 8 20.0 
2.00 13 32.5 
3.00 1 2.5 
4.00 7 17.5 
5.00 1 2.5 
6.00 5 12.5 
8.00 1 2.5 
14.00 1 2.5 
 
Blood transfusion (PlateletBlood transfusion) 
 
 
Frequency Percent Valid Percent Cumulative Percent 
Valid 
.00 23 57.5 57.5 57.5 
2.00 9 22.5 22.5 80.0 
4.00 7 17.5 17.5 97.5 
8.00 1 2.5 2.5 100.0 
Total 40 100.0 100.0  
 
Blood transfusion (PlateletBlood transfusion) 
Particulars 
No.of respondents 
(n=40) 
Percentage 
(100%) 
.00 23 57.5 
2.00 9 22.5 
4.00 7 17.5 
8.00 1 2.5 
 
Viral markers 
 
 
Frequency Percent Valid Percent Cumulative Percent 
Valid 0.00 40 100.0 000.0 100.0 
 
Viral markers 
Particulars 
No.of respondents 
(n=40) 
Percentage 
(100%) 
0.00 40 000.0 
 
Serum Uric Acid 
 
 
Frequency Percent Valid Percent Cumulative Percent 
Valid 
4.50 3 7.5 7.5 7.5 
5.20 2 5.0 5.0 12.5 
5.60 5 12.5 12.5 25.0 
5.80 3 7.5 7.5 32.5 
6.00 1 2.5 2.5 35.0 
6.20 2 5.0 5.0 40.0 
6.40 1 2.5 2.5 42.5 
6.50 4 10.0 10.0 52.5 
6.60 2 5.0 5.0 57.5 
6.80 7 17.5 17.5 75.0 
7.00 5 12.5 12.5 87.5 
7.30 1 2.5 2.5 90.0 
7.50 3 7.5 7.5 97.5 
7.80 1 2.5 2.5 100.0 
Total 40 100.0 100.0  
 
Serum Uric Acid 
Particulars 
No.of respondents 
(n=40) 
Percentage 
(100%) 
4.50 3 7.5 
5.20 2 5.0 
5.60 5 12.5 
5.80 3 7.5 
6.00 1 2.5 
6.20 2 5.0 
6.40 1 2.5 
6.50 4 10.0 
6.60 2 5.0 
6.80 7 17.5 
7.00 5 12.5 
7.30 1 2.5 
7.50 3 7.5 
7.80 1 2.5 
 
 
Seizure 
 
 
Frequency Percent Valid Percent Cumulative Percent 
Valid 
Absent 32 80.0 80.0 80.0 
Present 8 20.0 20.0 100.0 
Total 40 100.0 100.0  
 
 
Seizure 
Particulars 
No.of respondents 
(n=40) 
Percentage 
(100%) 
Absent 32 80.0 
Present 8 20.0 
 
 
 
Hepetic Encephalopathy 
 
 
Frequency Percent Valid Percent Cumulative Percent 
Valid 
Absent 38 95.0 95.0 95.0 
Present 2 5.0 5.0 100.0 
Total 40 100.0 100.0  
 
Hepetic Encephalopathy 
Particulars 
No.of respondents 
(n=40) 
Percentage 
(100%) 
Absent 38 95.0 
Present 2 5.0 
 
 
IUD 
 
 
Frequency Percent Valid Percent Cumulative Percent 
Valid 
Absent 32 80.0 80.0 80.0 
Present 8 20.0 20.0 100.0 
Total 40 100.0 100.0  
 
IUD 
Particulars 
No.of respondents 
(n=40) 
Percentage 
(100%) 
Absent 32 80.0 
Present 8 20.0 
 
 
 
Bleeding manifestation 
 
 
Frequency Percent Valid Percent Cumulative Percent 
Valid 
Absent 35 87.5 87.5 87.5 
Present 5 12.5 12.5 100.0 
Total 40 100.0 100.0  
 
Bleeding manifestation 
Particulars 
No.of respondents 
(n=40) 
Percentage 
(100%) 
Absent 35 87.5 
Present 5 12.5 
 
 
 
 
Complication 
 
 
Frequency Percent Valid Percent Cumulative Percent 
Valid 
Absent 26 65.0 65.0 65.0 
Present 14 35.0 35.0 100.0 
Total 40 100.0 100.0  
 
Complication 
Particulars 
No.of respondents 
(n=40) 
Percentage 
(100%) 
Absent 26 65.0 
Present 14 35.0 
 
 
Mode of Delivery 
 
 
Frequency Percent Valid Percent Cumulative Percent 
Valid 
Normal 16 40.0 40.0 40.0 
Caeserian 24 60.0 60.0 100.0 
Total 40 100.0 100.0  
 
Mode of Delivery 
Particulars 
No.of respondents 
(n=40) 
Percentage 
(100%) 
Normal 16 40.0 
Caeserian 24 60.0 
 
 
 
 
Diagnosis Delivery intervel <12 
 
 
Frequency Percent Valid Percent Cumulative Percent 
Valid 
Negative 32 80.0 80.0 80.0 
Positive 8 20.0 20.0 100.0 
Total 40 100.0 100.0  
 
Diagnosis Delivery intervel <12 
Particulars 
No.of respondents 
(n=40) 
Percentage 
(100%) 
Negative 32 80.0 
Positive 8 20.0 
 
 
Diagnosis Delivery intervel 12-24 
 
 
Frequency Percent Valid Percent Cumulative Percent 
Valid 
Negative 23 57.5 57.5 57.5 
Positive 17 42.5 42.5 100.0 
Total 40 100.0 100.0  
 
Diagnosis Delivery intervel 12-24 
Particulars 
No.of respondents 
(n=40) 
Percentage 
(100%) 
Negative 23 57.5 
Positive 17 42.5 
 
 
 
 
Diagnosis Delivery intervel >24 
 
 
Frequency Percent Valid Percent Cumulative Percent 
Valid 
Negative 25 62.5 62.5 62.5 
Positive 15 37.5 37.5 100.0 
Total 40 100.0 100.0  
 
Diagnosis Delivery intervel >24 
Particulars 
No.of respondents 
(n=40) 
Percentage 
(100%) 
Negative 25 62.5 
Positive 15 37.5 
 
Diagnosis Delivery intervel 
 
 
Frequency Percent Valid Percent Cumulative Percent 
Valid 
<12 8 20.0 20.0 20.0 
12 to 24 17 42.5 42.5 62.5 
>24 15 37.5 37.5 100.0 
Total 40 100.0 100.0  
 
Diagnosis Delivery intervel 
Particulars 
No.of respondents 
(n=40) 
Percentage 
(100%) 
<12 8 20.0 
12 to 24 17 42.5 
>24 15 37.5 
 
 
 
Diagnosis Delivery intervel 
 
 
Frequency Percent Valid Percent Cumulative Percent 
Valid 
<24 25 62.5 62.5 62.5 
>24 15 37.5 37.5 100.0 
Total 40 100.0 100.0  
 
Diagnosis Delivery interval 
Particulars 
No.of respondents 
(n=40) 
Percentage 
(100%) 
<24 25 62.5 
>24 15 37.5 
 
NICU 
 
 
Frequency Percent Valid Percent Cumulative Percent 
Valid 
No 13 32.5 32.5 32.5 
Yes 27 67.5 67.5 100.0 
Total 40 100.0 100.0  
NICU 
Particulars 
No.of respondents 
(n=40) 
Percentage 
(100%) 
No 13 32.5 
Yes 27 67.5 
 
 
 
 
 
 
No NICU 
 
 
Frequency Percent Valid Percent Cumulative Percent 
Valid 
No 35 87.5 87.5 87.5 
Yes 5 12.5 12.5 100.0 
Total 40 100.0 100.0  
 
 
 
NICU 
 
 
Frequency Percent Valid Percent Cumulative Percent 
Valid 
NA 9 22.5 22.5 22.5 
NICU 27 67.5 67.5 90.0 
No NICU 4 10.0 10.0 100.0 
Total 40 100.0 100.0  
 
 
 
No NICU 
Particulars 
No.of respondents 
(n=40) 
Percentage 
(100%) 
No 35 87.5 
Yes 5 12.5 
 
 
 
 
 
 
 
Table No – 19 
 NICU 
Particulars 
No.of respondents 
(n=40) 
Percentage 
(100%) 
NA 9 22.5 
NICU 27 67.5 
No NICU 4 10.0 
 
Diagrams No – 19 
 
 
Perinatal Mortality 
 
 
Frequency Percent Valid Percent Cumulative Percent 
Valid 
Absent 19 47.5 47.5 47.5 
Present 21 52.5 52.5 100.0 
Total 40 100.0 100.0  
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Perinatal Mortality 
Particulars 
No.of respondents 
(n=40) 
Percentage 
(100%) 
Absent 19 47.5 
Present 21 52.5 
 
Maternal Mortality 
 
 
Frequency Percent Valid Percent Cumulative Percent 
Valid 
Absent 37 92.5 92.5 92.5 
Present 3 7.5 7.5 100.0 
Total 40 100.0 100.0  
 
 
 
Maternal Mortality 
Particulars 
No.of respondents 
(n=40) 
Percentage 
(100%) 
Absent 37 92.5 
Present 3 7.5 
 
 
Delivery recovery time <7 days 
 
 
Frequency Percent Valid Percent Cumulative Percent 
Valid 
Negative 22 55.0 55.0 55.0 
Positive 18 45.0 45.0 100.0 
Total 40 100.0 100.0  
 
Delivery recovery time <7 days 
Particulars 
No.of respondents 
(n=40) 
Percentage 
(100%) 
Negative 22 55.0 
Positive 18 45.0 
 
 
Delivery recovery time 7 to 14days 
 
 
Frequency Percent Valid Percent Cumulative Percent 
Valid 
Negative 30 75.0 75.0 75.0 
Positive 10 25.0 25.0 100.0 
Total 40 100.0 100.0  
 
Delivery recovery time 7 to 14days 
Particulars 
No.of respondents 
(n=40) 
Percentage 
(100%) 
Negative 30 75.0 
Positive 10 25.0 
 
 
Delivery recovery time 14days 
 
 
Frequency Percent Valid Percent Cumulative Percent 
Valid 
Negative 34 85.0 85.0 85.0 
Positive 6 15.0 15.0 100.0 
Total 40 100.0 100.0  
 
 
 
 
 
Delivery recovery time 14days 
Particulars 
No.of respondents 
(n=40) 
Percentage 
(100%) 
Negative 34 85.0 
Positive 6 15.0 
 
 
Delivery recovery time 
 
 
Frequency Percent Valid Percent Cumulative Percent 
Valid 
NA 6 15.0 15.0 15.0 
<7days 18 45.0 45.0 60.0 
7 to 14days 10 25.0 25.0 85.0 
>14 days 6 15.0 15.0 100.0 
Total 40 100.0 100.0  
 
Delivery recovery time 
Particulars 
No.of respondents 
(n=40) 
Percentage 
(100%) 
NA 6 15.0 
<7days 18 45.0 
7 to 14days 10 25.0 
>14 days 6 15.0 
 
 
Delivery recovery time 
 
 
Frequency Percent Valid Percent Cumulative Percent 
Valid 
NA 6 15.0 15.0 15.0 
<7 days 18 45.0 45.0 60.0 
Above 7days 16 40.0 40.0 100.0 
Total 40 100.0 100.0  
 
 
Table No – 20 
Delivery recovery time 
Particulars 
No.of respondents 
(n=40) 
Percentage 
(100%) 
NA 6 15.0 
<7 days 18 45.0 
Above 7days 16 40.0 
 
 
 
Diagrams No – 20 
 
 
 
 
6
18
16
0
2
4
6
8
10
12
14
16
18
NA <7 days Above 7days
 Diagnosis 
 
 
Frequency Percent Valid Percent Cumulative Percent 
Valid 
AFLP 3 7.5 7.5 7.5 
Cirrhosis 3 7.5 7.5 15.0 
CRIGGLER NAJAR SYN 1 2.5 2.5 17.5 
Help 14 35.0 35.0 52.5 
Partial help 19 47.5 47.5 100.0 
Total 40 100.0 100.0  
 
Diagnosis 
Particulars 
No.of respondents 
(n=40) 
Percentage 
(100%) 
AFLP 3 7.5 
Cirrhosis 3 7.5 
CRIGGLER NAJAR SYN 1 2.5 
Help 14 35.0 
Partial help 19 47.5 
 
 
Table No – 21 
Diagnosis 
Particulars 
No.of respondents 
(n=40) 
Percentage 
(100%) 
AFLP 3 7.5 
Cirrhosis 3 7.5 
CRIGGLER NAJAR SYN 1 2.5 
Help 14 35.0 
Partial help 19 47.5 
 
 Diagrams No – 21 
 
 
 
 
 
Diagnosis 
 
 
Frequency Percent Valid Percent Cumulative Percent 
Valid 
Hellp 33 82.5 82.5 82.5 
Non-Hellp 7 17.5 17.5 100.0 
Total 40 100.0 100.0  
 
Table No – 22 
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AFLP Cirrhosis CRIGGLER NAJAR SYN Help Partial help
Diagnosis 
Particulars 
No.of respondents 
(n=40) 
Percentage 
(100%) 
Hellp 33 82.5 
Non-Hellp 7 17.5 
 
Diagrams No – 22 
 
 
Descriptives 
Descriptive Statistics 
 
 
N Minimum Maximum Mean Std. Deviation 
Age 40 22 34 26.80 3.353 
BP1 40 110 160 138.75 16.823 
BP2 40 70 100 90.00 7.511 
HB 40 6.00 9.80 7.7800 1.05519 
Hellp, 33
Non-Hellp, 7
Hellp Non-Hellp
Urea 40 24.00 73.00 39.5250 8.73539 
Creatinine 40 .80 2.20 1.3250 .44592 
Bilirubin 40 1.40 11.70 3.1125 1.97318 
SGPT 40 56.00 253.00 111.6500 45.19505 
SGOT 40 60.00 278.00 127.1500 52.38396 
RBS 40 60.00 250.00 117.9750 40.39643 
LDH 40 300.00 830.00 492.8500 99.25558 
Clotting time 40 3 14 5.83 2.374 
Blood transfusion (WBBlood transfusion) 40 .00 6.00 2.4250 1.44803 
Blood transfusion (FFPBlood transfusion) 40 .00 14.00 3.0500 2.65011 
Blood transfusion (PlateletBlood transfusion) 40 .00 8.00 1.3500 1.88856 
Viral markers 40 1.00 1.00 1.0000 .00000 
Serum Uric Acid 40 4.50 7.80 6.3375 .83993 
Valid N (listwise) 40     
 
 
 
 
 
Descriptives 
Items N Min. Max. S.D Mean 
Age 40 22 34 3.353 26.80 
BP1 40 110 160 16.823 138.75 
BP2 40 70 100 7.511 90.00 
HB 40 6.00 9.80 1.05519 7.7800 
Urea 40 24.00 73.00 8.73539 39.5250 
Creatinine 40 .80 2.20 .44592 1.3250 
Bilirubin 40 1.40 11.70 1.97318 3.1125 
SGPT 40 56.00 253.00 45.19505 111.6500 
SGOT 40 60.00 278.00 52.38396 127.1500 
RBS 40 60.00 250.00 40.39643 117.9750 
LDH 40 300.00 830.00 99.25558 492.8500 
Clotting time 40 3 14 2.374 5.83 
Blood transfusion (WBBlood transfusion) 40 .00 6.00 1.44803 2.4250 
Blood transfusion (FFPBlood transfusion) 40 .00 14.00 2.65011 3.0500 
Blood transfusion (PlateletBlood transfusion) 40 .00 8.00 1.88856 1.3500 
Viral markers 40 1.00 1.00 .00000 1.0000 
Serum Uric Acid 40 4.50 7.80 .83993 6.3375 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
RESULTS 
 
 
 
 
 
 
 
 
 
 
 
 
 RESULTS 
OBSTETRIC CODE 
In our study of non infective jaundice in pregnancy, more number of patients 
belonged to the primi gravida category (62.5%) than multi gravid ( 37.5%) 
INCIDENCE 
Among the incidence of all the non infective jaundice cases HELLP and 
PARTIAL HELLP were the most common and together comprised  a staggering 
(82.5%) of the patients. The rest 17.5% included cases of AFLP, cirrhosis  and 
criggler najar syndrome. 
GESTATIONAL AGE 
Most of the pregnancy complicated by the non infective jaundice in this 
study presented at a gestational age earlier than 37 weeks (70%) when compared to 
the (30%) who presented at term. 
BLOOD PRESSURE 
In our study patients with higher BP reading >130/90 (62.5%) at the time of 
admission manifested a more severe course of the disease as evidenced by higher 
complications, higher maternal and fetal morbidity and mortality. 
 
 
 
 
 
PRE ECLAMPTIC FEATURES 
95% patients who constituted the study presented with preeclamptic features 
of pedal edema ,abdominal wall edema and urine albumin showed higher incidence 
of partial HELLP and HELLP syndrome. 
 
BILIRUBIN 
It was observed that patients with bilirubin values higher than the standard 
deviations of 1.5mg/dl (95%) in our study were more prone for higher risk of 
complications. 
DIAGNOSIS DELIVERY INTERVAL 
In our study it was observed that patient who delivered within 24hrs (28.6%) 
of diagnosis showed better prognosis as evidenced by milder course of the disease, 
lesser incidence of complications and no maternal mortality 
MATERNAL MORTALITY 
In my study, multi gravida presented with severe form of the disease had 
higher incidence of maternal mortality the features with increased maternal 
mortality were cirrhosis with portal hypertension 
  
DELIVERY RECOVERY TIME 
 Many patients presented with Bp<130/90 (37.5%) in our study showed 
recovery within 7 days when compared to 40 % of those with Bp > 130/90  who 
recovered in a week. 
GESTATIONAL AGE- NICU ADMISSION 
In this study, the babies born to mother who presented with the disease at the 
gestational age <37 weeks showed higher morbidity as observed by admission in 
NICU (70.4%) whereas only (29.6%) of the babies delivered in term patients with 
non infective jaundice were admitted in NICU. 
 
 
 
  
CONCLUSION 
 
 
 
  
CONCLUSION 
 
HELLP constitutes most of the causes of non infective jaundice ,it 
leads to increased maternal morbidity than mortality. Hence mortality is 
preventable with early diagnosis. 
Higher blood pressure reading showed higher risk of complications 
Higher bilirubin values and altered LFT were more prone for severe 
manifestations of the disease. Advanced maternal age at gestation are higher 
risk of complication. Cirrhosis with portal hypertension was found to be the 
cause of maternal mortality among all causes of non infective jaundice in a 
tertiary care centre. 
Early intervention and delivery of the fetus within 24hrs reduces the 
incidence of complications and improved prognosis and reduce delivery 
recovery time. 
Patients presented with lower BP recovered earlier Preterm babies of 
affected mothers ran a higher risk of complications 
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